IceCure Medical (ICCM) Stock Price, News & Analysis

Company Overview

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key Stats

• Today's Range: $1.14 to $1.20
• 50-Day Range: $1.07 to $1.52
• 52-Week Range: $0.48 to $1.66
• Volume: 140,571 shs
• Average Volume: 474,009 shs
• Market Capitalization: $64.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Strong Buy

IceCure Medical Stock Analysis - MarketRank™

IceCure Medical scored higher than 43% of companies evaluated by MarketBeat, and ranked 499th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

IceCure Medical has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IceCure Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IceCure Medical are expected to grow in the coming year, from ($0.28) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IceCure Medical is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IceCure Medical is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IceCure Medical has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently decreased by 19.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IceCure Medical does not currently pay a dividend.

Dividend Growth

IceCure Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.80% of the float of IceCure Medical has been sold short.

Short Interest Ratio / Days to Cover

IceCure Medical has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IceCure Medical has recently decreased by 19.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for IceCure Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IceCure Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.44% of the stock of IceCure Medical is held by insiders.

Percentage Held by Institutions

Only 0.62% of the stock of IceCure Medical is held by institutions.

ICCM Stock Analysis - Frequently Asked Questions

How have ICCM shares performed this year?

IceCure Medical's stock was trading at $1.10 at the beginning of the year. Since then, ICCM stock has increased by 6.4% and is now trading at $1.17.
View the best growth stocks for 2025 here.

How were IceCure Medical's earnings last quarter?

IceCure Medical Ltd (NASDAQ:ICCM) released its quarterly earnings data on Thursday, March, 27th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. The firm earned $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative trailing twelve-month return on equity of 124.44% and a negative net margin of 376.85%.
Read the conference call transcript.

How do I buy shares of IceCure Medical?

Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IceCure Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IceCure Medical investors own include Medical Properties Trust (MPW), Realty Income (O), Oxford Square Capital (OXSQ), PayPal (PYPL), A.P. Møller - Mærsk A/S (AMKBY), Annaly Capital Management (NLY) and Oxford Lane Capital (OXLC).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 5/04/2025
• Next Earnings (Estimated): 5/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:ICCM
• CIK: 1584371
• Web: www.icecure-medical.com
• Phone: 972-4623-0333
• Fax: 972-4623-0222
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.50
• High Stock Price Target: $2.50
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +113.7%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,650,000.00
• Net Margins: -376.85%
• Pretax Margin: N/A
• Return on Equity: -124.44%
• Return on Assets: -87.70%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 2.67
• Quick Ratio: 2.27

Sales & Book Value

• Annual Sales: $3.29 million
• Price / Sales: 19.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 4.33

Miscellaneous

• Outstanding Shares: 55,502,000
• Free Float: 54,148,000
• Market Cap: $64.94 million
• Optionable: Not Optionable
• Beta: 0.43